A 35-year-old woman presented with paraparesis, T7 sensory level, and urinary retention 5 days after developing chickenpox. Spinal cord MRI showed a longitudinally extensive myelitis ([figure 1](#F1){ref-type="fig"}). Despite treatment with IV methylprednisolone (1 g/d × 5) and acyclovir (10 mg/kg/8 h × 3 weeks), the patient developed complete paraplegia, bilateral arm paresis, and a cervicothoracic sensory level. New MRI showed a cystic-like cervical lesion and patchy signs of subacute hemorrhage with gadolinium enhancement from C7 to conus ([figure 1](#F1){ref-type="fig"}). The follow-up MRI 18 months later showed severe spinal cord atrophy below C7 with hemosiderin deposit ([figure 2](#F2){ref-type="fig"}). The MRI findings, and the devastating evolution, mirror the pathologic features described in acute ascending necrotizing myelitis.^[@R1]^

![Spinal cord MRI features at onset\
At onset, sagittal MRI shows an extensive cervicothoracic T2 hyperintensity (A.a and A.b). After 3 weeks of therapy, the extensive lesion persists (B.a and B.b) and shows a central cystic-like lesion at C4 level (B.a and B.c, arrows), suggestive signs of subacute hemorrhage (T1 hyperintensity; B.c, arrowhead), and gadolinium enhancement from C7 level (B.d, arrow).](NEURIMMINFL2017013011FF1){#F1}

![Severe spinal cord atrophy at long term\
Follow-up MRI 18 months later reveals a longitudinally severe spinal cord atrophy from C7 to conus (A and B, arrows). Note the filiform aspect of the spinal cord (axial T2-weighted image; D, arrowhead), and the hypointensity in T2 (B), and T2 gradient echo--weighted (C) images suggestive of hemosiderin deposit.](NEURIMMINFL2017013011FF2){#F2}
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